The submission system has been updated — tell us of any problems

Phillip Nicolson | GMC# 7016987

  • University Hospitals Birmingham NHS Foundation Trust
  • Consultant Haematologist

Declaration on 3 July 2024

Declaration period: 2024

Main employment

  • Type: NHS
  • Details: Consultant Haematologist / UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST

Other work

  • Relates to: Commercial relationships
  • Income band: £2,000 to under £5,000
  • Details: Took part in a promotional podcast for Sobi. £2100 to cover time for preparation, podcast recording and travel.

Declaration on 3 March 2024

Declaration period: 2024

Other work

  • Relates to: Commercial relationships
  • Income band: £1,000 to under £2,000
  • Details: Speaker Fees for Educational Lecture from Sobi - Swedish Orphan Biovitrum Ltd (UK). £1120. Limitations on the talk were that I could not mention specific medicines by name and had to remove a slide talking about structure of EHL Factor 8 and 9 molecules.

Declaration on 30 November 2023

Declaration period: 2023

Main employment

  • Type: NHS
  • Details: Consultant Haematologist / University Hospitals Birmingham NHS Foundation Trust

Academic

  • Relates to: Research grants
  • Income band: £100,000+
  • Details: Co-Investigator on British Heart Foundation Project Grant: £236,336. Principle Investigator on National Institute for Health & Care Research Biomedical Research Centre Public Involvement Fund: £300.

Sponsored / educational events

  • Relates to: Conferences
  • Income band: £100 to under £1,000
  • Details: £200 for being on a panel at an Astra Zeneca sponsored symposium as part of the 'Let's Talk Clots' event run by Thrombosis UK. Talk was themed around use of DOACs and how to reverse them if bleeding. Included information on PCC and Andexanet Alfa

Declaration on 23 September 2023

Declaration period: 2022

Main employment

  • Type: Academic
  • Details: Associate Clinical Professor in Cardiovascular Medicine / University of Birmingham

Academic

  • Relates to: Research grants
  • Income band: £50,000 to under £100,000
  • Details: £88,000 (PI) AstraZeneca. RAPIDO: A HaemSTAR-led UK national audit of the use of Reversal Agents in Patients antIcoagulated with Direct Oral anticoagulants. £10,000 (PI) Dudley Leukaemia Unit Appeal Fund. RAPIDO: A HaemSTAR-led UK national audit of the use of Reversal Agents in Patients antIcoagulated with Direct Oral anticoagulants.

Something wrong with this declaration? Contact team@sunshineuk.org to let them know.